title: Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.
abstract: OBJECTIVE
  In a retrospective study using stereotactic body radiotherapy (SBRT) in medically inoperable patients with stage I NSCLC we previously reported a local control rate of 88% utilizing a median dose of 15Gyx3. This report records the toxicity encountered in a prospective phase II trial, and its relation to coexisting chronic obstructive pulmonary disease (COPD) and cardio vascular disease (CVD).
  
  
  METHODS
  Sixty patients were entered in the study between August 2003 and September 2005. Fifty-seven patients (T1 65%, T2 35%) with a median age of 75 years (59-87 years) were evaluable. The baseline mean FEV1% was 64% and median Karnofsky index was 80. A total dose of 45Gy was delivered in three fractions at the 67% isodose of the PTV. Clinical, pulmonary and radiological evaluations were made at 6 weeks, 3, 6, 9, 12, 18, and 36 months post-SBRT. Toxicity was graded according to CTC v2.0 and performance status was graded according to the Karnofsky scale.
  
  
  RESULTS
  At a median follow-up of 23 months, 2 patients had relapsed locally. No grade 4 or 5 toxicity was reported. Grade 3 toxicity was seen in 12 patients (21%). There was no significant decline of FEV1% during follow-up. Low grade pneumonitis developed to the same extent in the CVD 3/17 (18%) and COPD 7/40 (18%) groups. The incidence of fibrosis was 9/17 (53%) and pleural effusions was 8/17 (47%) in the CVD group compared with 13/40 (33%) and 5/40 (13%) in the COPD group.
  
  
  CONCLUSIONS
  SBRT for stage I NSCLC patients who are medically inoperable because of COPD and CVD results in a favourable local control rate with a low incidence of grade 3 and no grade 4 or 5 toxicity.
authors.affiliation: Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden.
authors.forename: Pia
authors.initials: P
authors.lastname: Baumann
authors.forename: Jan
authors.initials: J
authors.lastname: Nyman
authors.forename: Morten
authors.initials: M
authors.lastname: Hoyer
authors.forename: Giovanna
authors.initials: G
authors.lastname: Gagliardi
authors.forename: Ingmar
authors.initials: I
authors.lastname: Lax
authors.forename: Berit
authors.initials: B
authors.lastname: Wennberg
authors.forename: Ninni
authors.initials: N
authors.lastname: Drugge
authors.forename: Lars
authors.initials: L
authors.lastname: Ekberg
authors.forename: Signe
authors.initials: S
authors.lastname: Friesland
authors.forename: Karl-Axel
authors.initials: KA
authors.lastname: Johansson
authors.forename: Jo-Smund
authors.initials: JS
authors.lastname: Lund
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Morhed
authors.forename: Kristina
authors.initials: K
authors.lastname: Nilsson
authors.forename: Nina
authors.initials: N
authors.lastname: Levin
authors.forename: Merete
authors.initials: M
authors.lastname: Paludan
authors.forename: Christer
authors.initials: C
authors.lastname: Sederholm
authors.forename: Anders
authors.initials: A
authors.lastname: Traberg
authors.forename: Lena
authors.initials: L
authors.lastname: Wittgren
authors.forename: Rolf
authors.initials: R
authors.lastname: Lewensohn